Skin Elements Raises $2.5 Million to Commercialize SE Formula Biotechnology Platform
Key Insights
Skin Elements Limited (search) secured $2.5 million in funding through a two-tranche placement at $0.002 per share to advance its SE Formula (search) biotechnology development program.
The Australian natural biotechnology company will allocate $1.2 million specifically for scaling the SE Formula (search) launch into commercialization, with additional funds for working capital.
The placement includes free attaching options exercisable at $0.006 and will result in significant dilution of approximately 64% for existing shareholders.
Skin Elements Limited (search) (ASX: SKN), an Australian natural biotechnology company, has secured $2.5 million in funding through a two-tranche placement to advance its SE Formula (search) biotechnology development program. The placement, priced at $0.002 per share, includes one free attaching unquoted option for every two shares issued, with options exercisable at $0.006 and expiring three years from the issue date.
Funding Structure and Timeline
The placement is structured across two tranches, with the first tranche of $315,000 involving the issue of 157,500,000 shares under existing ASX listing rules. The second tranche, totaling $2,185,000, will comprise 1,092,500,000 shares and 625,000,000 options, subject to shareholder approval at the company's Annual General Meeting scheduled for late November 2025.
The placement price represents a 33% discount to the last closing price of $0.003 and a 19% discount to the 15-trading day volume weighted average trading price up to October 10, 2025. 62 Capital Pty Ltd (search) served as the sole lead manager for the placement, receiving a 6% capital raising fee plus GST.
Commercial Development Focus
According to Skin Elements, the funding will be strategically allocated across key development areas. The company plans to invest $1.2 million specifically for the SE Formula (search) scale launch into commercialization, representing the largest portion of the raised capital. An additional $1.15 million will support working capital requirements, while $150,000 will cover issuance costs.
The SE Formula (search) represents the company's award-winning biotechnology platform, though specific details about its therapeutic applications or target markets were not disclosed in the funding announcement.
Shareholder Impact and Ownership Structure
The placement will result in the issuance of 1.25 billion shares, representing approximately 116% of the currently issued shares. Existing shareholders will experience dilution of approximately 64% as a result of the placement. The company has structured the placement to ensure no single investor will hold a relevant interest greater than 20%, and confirmed that no investor is an associate of any other investor participating in the funding round.
The significant dilution reflects the company's current capital requirements to advance its biotechnology program toward commercial readiness, marking a critical transition phase for the SE Formula (search) development program.